Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:45 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Patients With Measurable Residual Disease Positive B-cell Acute Lymphoblastic Leukemia
NCT07192237 · M.D. Anderson Cancer Center · PHASE2 · suspended · last registry update 2026-10-08 · Childhood acute lymphoblastic leukemia · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “PI requested” | – | Registry record, M.D. Anderson Cancer Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CD3E in childhood acute lymphoblastic leukemia within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-09-25Results posted on the registry: M.D. Anderson Cancer Center, Blinatumomab (NCT02458014)
- 2026-07-23Phase 3 first posted: Institute of Hematology & Blood Diseases Hospital, China, BLB101 for Injection + Blinatumomab for Injection (NCT07723911)
- 2026-06-09Results posted on the registry: University of California, Davis, Blinatumomab + Ibrutinib (NCT02997761)
- 2026-05-13Results posted on the registry: Amgen, Blinatumomab (NCT06649006)
- 2026-05-06Phase 3 first posted: Merck Sharp & Dohme LLC, MK-1045 + Blinatumomab (NCT07570173)
- 2026-03-17Phase 3 first posted: Charite University, Berlin, Germany, Inotuzumab ozogamicin (INO) + Blinatumomab (NCT07476729)
- 2026-03-04Results posted on the registry: St. Jude Children's Research Hospital, Cyclophosphamide + Fludarabine (NCT03849651)
- 2025-12-22Phase 3 first posted: Bambino Gesù Hospital and Research Institute, Ruxolitinib + Blinatumomab (NCT07297914)
- 2025-10-31Phase 3 first posted: Amgen, Blinatumomab + Blinatumomab (NCT07223190)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision